{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"17"}],"title":"Responder"},{"measurements":[{"groupId":"OG000","value":"199"},{"groupId":"OG001","value":"219"}],"title":"Non-Responder"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"240"},{"groupId":"OG001","value":"236"}],"units":"Participants"}],"description":"To evaluate objective response rate (ORR) determined by central radiology assessment per mRECIST, version 1.1 in patients with advanced GIST treated with avapritinib compared to patients treated with regorafenib. A complete response (CR) per modified Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) is defined as complete disappearance of all target lesions. A partial response (PR) is defined as at least 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum of diameters. Overall Response (OR) = CR + PR","groups":[{"description":"300 mg PO QD avapritinib: Avapritinib tablets for oral administration. Avapritinib will be dosed at 300 mg once daily, continuously.","id":"OG000","title":"Avapritinib"},{"description":"160 mg PO QD regorafenib: Regorafenib tablets for oral administration. Regorafenib will be dosed at 160 mg once daily for 3 weeks out of every 4 weeks (ie. 3 weeks on/1 week off).","id":"OG001","title":"Regorafinib"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Intent-to-Treat Population that included all patients randomized to study.","reportingStatus":"POSTED","timeFrame":"24 Months","title":"Objective Response Rate (ORR) Determined by Central Radiology Assessment Per mRECIST, Version 1.1","type":"SECONDARY","unitOfMeasure":"Participants"}